


PCR2020 e-Course

Flash report



e-Ultimaster

The biggest real world
BP-DES registry
crossing 4 continents⁽¹⁻²⁾



e-Ultimaster registry

37,198 patients enrolled

Clinical follow-up

0d

3m

1y

An independent Clinical Events Committee reviewed and adjudicated all endpoint-related serious adverse events

Dual antiplatelet therapy(DAPT) was at the discretion of the operator

Primary endpoint

Target lesion failure at 1 year

Cardiac death, target vessel MI or clinically driven target lesion revascularization

Secondary endpoint

Safety

Cardiac death/myocardial infarction
Stent thrombosis (according to ARC definitions; acute, subacute and late) Major vascular and bleeding complications

Efficacy and patient-oriented endpoints

Target lesion revascularization (TLR)
Target vessel failure (TVF) (Cardiac death, target vessel MI or clinically driven target vessel revascularization)
Patient-oriented composite endpoint (POCE)
(All-cause death, any MI or any coronary revascularization)

Study devices

UltimasterTM Sirolimus Eluting Coronary Stent System

Platform Thin strut, CoCr Open cell design

Polymer PDLLA PCL copolymer resorbed within 3-4 months

Coating Abluminal Gradient coating

Drug Sirolimus


Learn more about Ultimaster BP-DES



Total population

"Ultimaster DES showed an excellent performance at 1 year with a TLF rate <5% in all continents and stent thrombosis rate <1% (1)"

Marco Roffi



Total patients: 37,198


Europe: 25,736 (69%)

Asia: 6,614 (18%)

Africa/Middle East: 2,438 (7%)

S America/Mexico: 2,410 (6%)

Clinical outcomes at 1 year



Are you interested in geographical difference?

Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



e-ULTIMASTER registry: final results and differences across continents


Bifurcation lesion

"4,395 patients with bifurcation lesions treated with Ultimaster DES showed excellent clinical outcomes with TLF 5.1% at 1 year ⁽²⁾"




Bernard Chevalier

Study protocol



POT vs No POT on Ultimaster



Are you interested in other Bifurcation techniques ?

Check more information on PCR online

True bifurcation vs other bifurcation

Final kissing vs No Final kissing

One stent vs Two stent

Log in -> Sessions -> Hotline and Innovation ->



Bifurcation stenting: role of deployment technique in a global registry

Multivessel disease


"Ultimaster DES demonstrated excellent results even in this complex population"³⁾




David Hildick-Smith

Clinical outcomes at 12 months

Propensity score adjusted



Study protocol



Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



**Complete revascularisation
with the Ultimaster stent**


Complex PCI subgroups

"Overall ischemic event rates at 1 year in patients undergoing complex PCI were generally low ⁽⁴⁾"


Mamas MAMAS



Study protocol



Clinical event rate at 1 year



Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



One-year clinical outcomes of complex PCI treated with use of Ultimster stent

Contact

